Quick Comparison

PinealonThymosin Beta-4
Half-LifeApproximately 30 minutes (extremely short — effects attributed to gene expression changes that outlast plasma exposure)1-2 hours
Typical DosageOral (capsule): 100-200 mg once daily for 10-30 day cycles, often repeated 2-3 times per year. Subcutaneous injection: 1-10 mg per dose, alternate days for 10-20 day cycles. Intranasal: 5-10 drops per nostril daily for 10-20 day cycles. Cycling rather than continuous use is the standard Khavinson protocol.Loading: 750 mcg-2 mg subcutaneous two or three times weekly for 2-4 weeks. Maintenance: 750 mcg-2 mg subcutaneous once or twice weekly. Some protocols use higher loading doses for acute injuries.
AdministrationOral capsule, subcutaneous injection, or intranasal spray (cycled)Subcutaneous injection
Research Papers5 papers30 papers
Categories

Mechanism of Action

Pinealon

Pinealon is a short tripeptide (Glu-Asp-Arg) belonging to the Khavinson family of peptide bioregulators — small peptides hypothesised to regulate gene expression in tissue-specific ways by binding directly to DNA promoter regions. Pinealon is the brain- and pineal-gland-targeted member of this family, designed to penetrate cells and the nuclear membrane to interact with promoter sequences of genes involved in neuronal function and circadian regulation.

Proposed mechanisms include modulation of melatonin synthesis pathways (via effects on pineal gland function), upregulation of antioxidant defence enzymes in neurons, and protection against oxidative stress from age-related accumulation of reactive oxygen species. Russian preclinical studies have reported pinealon-induced increases in expression of genes involved in serotonin and melatonin metabolism, neurotrophic factor signalling, and antioxidant capacity, alongside protective effects against neurotoxin-induced neuronal damage in animal models.

The extremely short plasma half-life (around 30 minutes) is a feature shared with all Khavinson tripeptides — the proposed model is that the peptides act as transient signalling molecules that trigger longer-lasting changes in gene expression, with effects persisting well beyond plasma clearance. This model would explain the use of pulse-dosing protocols (10-30 day courses repeated periodically) rather than continuous administration. Importantly, almost all published efficacy data comes from Russian research groups associated with the original Khavinson laboratory, and the bioregulator framework has not been independently validated in Western clinical settings. Mechanistic claims should be treated as preliminary, and clinical use remains largely anecdotal outside Russia.

Thymosin Beta-4

Thymosin Beta-4 (Tβ4) is a 43-amino-acid peptide and the most abundant member of the beta-thymosin family. Despite its name (derived from its original isolation from thymus tissue), Tβ4 is expressed in virtually every nucleated cell in the body and is particularly concentrated in platelets, wound fluid, and developing tissues. TB-500 is the commercially available active fragment.

The primary molecular function is G-actin sequestration. Tβ4 binds globular actin (G-actin) monomers at a 1:1 stoichiometric ratio through a central actin-binding domain (LKKTET motif), maintaining a large intracellular pool of unpolymerized actin available for rapid mobilization. When cells need to migrate — as during wound healing, inflammation, or development — Tβ4 releases G-actin for polymerization into filamentous actin (F-actin) at the cell's leading edge. This dynamic actin cycling is the fundamental force-generating mechanism for cell migration.

Beyond actin regulation, Tβ4 has extensive signaling functions. It promotes angiogenesis by stimulating endothelial cell migration, tubule formation, and the expression of VEGF and angiopoietin-1. It reduces inflammation by modulating NF-κB signaling, decreasing production of TNF-α, IL-1β, and other pro-inflammatory mediators. In wound healing, Tβ4 upregulates laminin-5 production — a key component of the basement membrane that guides epithelial cell migration during wound re-epithelialization. It activates cardiac progenitor cells and promotes cardiomyocyte survival following ischemic injury, an effect that has generated significant interest for cardiac repair applications.

Tβ4 also promotes stem cell migration and differentiation through activation of the Akt cell survival pathway. It stimulates hair follicle stem cell migration and differentiation, which has been observed as increased hair growth in animal studies. The combination of cell migration, angiogenesis, anti-inflammation, stem cell activation, and extracellular matrix remodeling makes Tβ4 one of the most comprehensive endogenous healing molecules identified.

Risks & Safety

Pinealon

Common

generally reported as well tolerated; mild headache or transient drowsiness occasionally reported.

Serious

very limited Western clinical data — long-term safety not established outside Russian research populations.

Rare

allergic reactions. Like other Khavinson bioregulators, the evidence base is thinner than the marketing suggests.

Thymosin Beta-4

Common

injection site irritation, headache, nausea, temporary fatigue.

Serious

may promote existing tumors by stimulating new blood vessel formation and cell movement, no long-term data on effects on tissue remodeling.

Rare

allergic reactions, localized infection.

Full Profiles